ON 108600
Based on 1 Customer Validation
ON 108600 (108600) is a CK2 (CK2α1: IC50 = 50 nM; CK2α2 = 5 nM), TNIK (IC50 = 5 nM) and DYRK (DYRK1A: IC50 = 16 nM; DYRK1B = 7 nM; DYRK2: = 28 nM). ON 108600 suppresses the growth of CD44high/CD24low breast cancer stem cell (BCSC) populations, induces G2/M arrest and apoptosis in triple negative breast cancer (TNBC) cells, and inhibits tubulin polymerization. ON 108600 can be used for the study of chemotherapy-resistant and metastatic TNBC.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.65%
- CAS No.: 1585246-23-6
- Formule: C22H14Cl2N2O6S2
- Masse moléculaire:537.39
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
Description
IC50 & Target
[1]|
DYRK2 0.028 μM (IC50) |
DYRK1A 0.016 μM (IC50) |
DYRK1B 0.007 μM (IC50) |
CK2α2 0.005 μM (IC50) |
CK2α1 0.05 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-22 | IC50 |
1 μM
Compound: 29; 108600
|
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
36876904 |
| MCF-10A | GI50 |
2.5 μM
|
Shows little or no toxicity against MCF-10A.
Shows little or no toxicity against MCF-10A.
|
34344863 |
| MDA-MB-231 | GI50 |
0.12 μM
|
Inhibits the viability of MDA-MB-231.
Inhibits the viability of MDA-MB-231.
|
34344863 |
| MDA-MB-157 | GI50 |
0.18 μM
|
Inhibits the viability of MDA-MB-157.
Inhibits the viability of MDA-MB-157.
|
34344863 |
| MDA-MB-436 | GI50 |
0.2 μM
|
Inhibits the viability of MDA-MB-436.
Inhibits the viability of MDA-MB-436.
|
34344863 |
| MDA-MB-468 | GI50 |
0.2 μM
|
Inhibits the viability of MDA-MB-468.
Inhibits the viability of MDA-MB-468.
|
34344863 |
| MDA-MB-453 | GI50 |
0.75 μM
|
Inhibits the viability of MDA-MB-453.
Inhibits the viability of MDA-MB-453.
|
34344863 |
| BT-20 | GI50 |
0.25 μM
|
Inhibits the viability of BT-20.
Inhibits the viability of BT-20.
|
34344863 |
| Hs-578T | GI50 |
0.15 μM
|
Inhibits the viability of Hs-587T.
Inhibits the viability of Hs-587T.
|
34344863 |
| HCC1806 | GI50 |
0.15 μM
|
Inhibits the viability of HCC1806.
Inhibits the viability of HCC1806.
|
34344863 |
| MCF7 | GI50 |
0.5 μM
|
Inhibits the viability of MCF7.
Inhibits the viability of MCF7.
|
34344863 |
| BT-474 | GI50 |
0.19 μM
|
Inhibits the viability of BT-474.
Inhibits the viability of BT-474.
|
34344863 |
| PBMC | GI50 |
> 10 μM
|
Inhibits the viability of PBMC.
Inhibits the viability of PBMC.
|
34344863 |
In Vitro
ON 108600 (108600) (24-72 h) inhibits the viability of TNBC cell lines MDA-MB-231, MDA-MB-468, Hs578T and BT-20, with GI50 values of 0.1-0.2 μM, and shows little or no toxicity against normal cells including MCF-10A, NBSC-1, NBSC-2, PBMC, HFL and hMSC-TERT (GI50 > 2.5 μM)[1].
ON 108600 (0.1-3 μM; 24 h) inhibits phosphorylation of CK2α substrate AKT1 (Ser129), DYRK1A substrates CYCLIN D1 (Thr286) and p27 (Ser10), and TNIK substrate AXIN2 in MDA-MB-231 and Hs578T cells[1].
ON 108600 (10-1000 nM; 72 h) suppresses colony and mammosphere formation of CD44high/CD24low BCSC populations purified from MDA-MB-231 and Hs578T cells[1].
ON 108600 exhibits inhibition against recombinant CK2α1, CK2α2, TNIK, DYRK1A, DYRK1B and DYRK2 kinases[1].
ON 108600 (72 h) induces G2/M arrest and apoptosis in MDA-MB-231 cells and CTG1883 TNBC organoids[1].
ON 108600 (1 μM; 12 h) induces abnormal mitotic spindle formation with multipolar spindles and multiple centrosomes in HeLa cells[1].
ON 108600 (72 h) inhibits growth and colony formation of Paclitaxel (HY-B0015)-resistant MDA-MB-231 and BT-20 cells (MDA-MB-231-TR and BT-20-TR) with the same efficiency as parental paclitaxel-sensitive cells[1].
ON 108600 (2.5 and 5 μM; 48 h) inhibits cell viability, induces G0/G1 arrest and apoptosis in metastatic canine mammary gland tumor (CMGT) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 (CD44high/CD24low), Hs578T (CD44high/CD24low)
-
Concentration:10, 100, 250, 500, 1000 nM
-
Incubation Time:72 h
-
Result:Suppressed colony formation in a dose-dependent manner.
Suppressed mammosphere formation in a dose-dependent manner.
-
Cell Line:MDA-MB-231, Hs578T
-
Concentration:0.1, 0.5, 1.0, 1.5, 3.0 μM
-
Incubation Time:24 h
-
Result:Inhibited phosphorylation of AKT1 (Ser129), CYCLIN D1 (Thr286) and p27 (Ser10).
Reduced AXIN2 expression in a dose-dependent manner.
-
Cell Line:MDA-MB-231, CTG1883 organoids
-
Concentration:0.125, 0.25, 0.5 μM
-
Incubation Time:24, 48, 72 h
-
Result:Induced G2/M arrest and increased sub-G1 fraction.
-
Cell Line:MDA-MB-231, CTG1883 organoids
-
Concentration:0.25, 0.5, 1.0, 1.5, 3.0 μM
-
Incubation Time:24,48 h
-
Result:Induced PARP and Caspase 3 cleavage in a dose-dependent manner.
-
Cell Line:HeLa
-
Concentration:1 μM
-
Incubation Time:12 h
-
Result:Induced abnormal mitotic spindle formation with multipolar spindles and multiple centrosomes.
-
Cell Line:Canine mammary gland tumor (CMGT) cells
-
Concentration:1, 2, 2.5, 3, 4, 5 μM
-
Incubation Time:24, 48 h
-
Result:Inhibited cell viability in a dose- and time-dependent manner, with approximately 50% reduction at 2.5-5 μM for 48 h.
-
Cell Line:Canine mammary gland tumor (CMGT) cells
-
Concentration:2.5, 5 μM
-
Incubation Time:48 h
-
Result:Increased late apoptotic cells from 2.65% to 29.65% and 48.50%, respectively.
-
Cell Line:Canine mammary gland tumor (CMGT) cells
-
Concentration:2.5, 5 μM
-
Incubation Time:48 h
-
Result:Induced G0/G1 arrest and increased G0/G1 population from 61.6% to 65.2% and 73.7%, respectively.
-
Cell Line:Canine mammary gland tumor (CMGT) cells
-
Concentration:2.5, 5 μM
-
Incubation Time:48 h
-
Result:Induced nuclear damage.
In Vivo
ON 108600 (50 or 100 mg/kg; i.p.; every other day for 21 days) inhibits tumor growth in MDA-MB-231 xenograft model in nude mice, without observable toxicity[1].
ON 108600 (100 mg/kg; i.p.; every other day for 21 days) suppresses tumor growth in TM00098 (Paclitaxel (HY-B0015)-sensitive TNBC PDX) model in NSG mice, without adverse effects on body weight[1].
ON 108600 (100 mg/kg; i.p.; every other day for 12-24 days) in combination with Paclitaxel synergistically suppresses tumor growth in chemotherapy-resistant TNBC PDX models (CTG1883 and CTG2397)[1].
ON 108600 (100 mg/kg; i.p.; every other day for 14 days) in combination with Paclitaxel (HY-B0015) suppresses growth of pre-established lung metastases in the MDA-MB-231/LM2-4/mCherry metastatic model in NSG mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CTG1883 PDX tumor-bearing female NSG mice (8-12 weeks old)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; every other day for 5 days
-
Result:Inhibited phosphorylation of pAKT1 Ser129 and pCYCLIN D1 Thr286.
Reduced C-MYC expression in tumors.
-
Animal Model:MDA-MB-231 xenograft-bearing female athymic nude mice (8-12 weeks old)[1]
-
Dosage:50, 100 mg/kg
-
Administration:i.p.; every other day for 21 days
-
Result:Inhibited tumor growth in a dose-dependent manner, with no observable toxicity or body weight loss.
-
Animal Model:TM00098 PDX tumor-bearing female NSG mice (8-12 weeks old)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; every other day for 21 days
-
Result:Suppressed tumor growth without adverse effects on body weight.
-
Animal Model:CTG1883 and CTG2397 PDX tumor-bearing female NSG mice (8-12 weeks old)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; every other day for 12-24 days
-
Result:Suppressed tumor growth.
-
Animal Model:MDA-MB-231/LM2-4/mCherry metastatic model (lung metastases) in female NSG mice (7 weeks old)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; every other day for 14 days
-
Result:Suppressed growth of pre-established lung metastases.
Chemical Information
-
CAS No. 1585246-23-6
-
Appearance Solid
-
Masse moléculaire 537.39
-
Formule C22H14Cl2N2O6S2
-
Color Brown to reddish brown
-
SMILES
ClC(C=CC=C1Cl)=C1CS(=O)(C2=CC=C(S/C(C(N3)=O)=C\C4=CC([N+]([O-])=O)=C(C=C4)O)C3=C2)=O
-
Synonyms
108600
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (186.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Pureté et documentation
-
Fiche technique (293 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8608 mL | 9.3042 mL | 18.6085 mL | 46.5211 mL |
| 5 mM | 0.3722 mL | 1.8608 mL | 3.7217 mL | 9.3042 mL | |
| 10 mM | 0.1861 mL | 0.9304 mL | 1.8608 mL | 4.6521 mL | |
| 15 mM | 0.1241 mL | 0.6203 mL | 1.2406 mL | 3.1014 mL | |
| 20 mM | 0.0930 mL | 0.4652 mL | 0.9304 mL | 2.3261 mL | |
| 25 mM | 0.0744 mL | 0.3722 mL | 0.7443 mL | 1.8608 mL | |
| 30 mM | 0.0620 mL | 0.3101 mL | 0.6203 mL | 1.5507 mL | |
| 40 mM | 0.0465 mL | 0.2326 mL | 0.4652 mL | 1.1630 mL | |
| 50 mM | 0.0372 mL | 0.1861 mL | 0.3722 mL | 0.9304 mL | |
| 60 mM | 0.0310 mL | 0.1551 mL | 0.3101 mL | 0.7754 mL | |
| 80 mM | 0.0233 mL | 0.1163 mL | 0.2326 mL | 0.5815 mL | |
| 100 mM | 0.0186 mL | 0.0930 mL | 0.1861 mL | 0.4652 mL |
Keywords
- ON 108600
- 1585246-23-6
- 108600
- ON108600
- ON-108600
- Casein Kinase
- DYRK
- Apoptosis
- Microtubule/Tubulin
- CK2α1
- CK2α2
- TNIK
- DYRK1A
- DYRK1B
- DYRK2
- multi-kinase inhibitor
- triple negative breast cancer (TNBC)
- breast cancer stem cell (BCSC)
- CD44high/CD24low
- G2/M arrest
- apoptosis
- tubulin polymerization
- chemotherapy-resistant
- metastasis
- MDA-MB-231
- Hs578T
- BT-20
- PDX model
- paclitaxel-resistant
- Inhibitor
- inhibitor
- inhibit